
	Harr currently serves as Managing Director and Head of Biotechnology Investment Banking at Morgan Stanley. Prior to his investment banking role at Morgan Stanley, Harr was the firm&#39;s biotech research analyst and co-head of global healthcare research, where he was consistently ranked as one of the top biotech analysts in the industry. He joins Juno after 12 years with Morgan Stanley, having managed more than $20 billion in financing deals and more than $40 billion in M&amp;A transactions as well as spending many years interacting with institutional investors as a research analyst.
